Condition
Primary Open Angle Glaucoma of Both Eyes
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 3 (2)
Trial Status
Completed4
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06016972Phase 2Completed
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
NCT05973305Phase 3CompletedPrimary
Comparative Study of Dorzol Eye Drops, 20 mg/ml Versus Trusopt® Eye Drops, 20 mg/ml
NCT05973318Phase 3CompletedPrimary
Comparative Study of Dorzotimol Eye Drops, 20 mg/mL + 5 mg/mL Versus Cosopt® Eye Drops, 20 mg/mL + 5 mg/mL
NCT03529591Not ApplicableCompleted
Is the Reduction in IOP After Treatment of 180 Degrees Equivalent to Treatment of 360 Degrees With SLT?
NCT04595227Unknown
Glaucoma Screening Using Dynamic Analysis of Computerized Pupillary Light Reflex Assessment Device
Showing all 5 trials